Swiss National Bank trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,693,408 shares of the medical research company’s stock after selling 18,900 shares during the period. Swiss National Bank owned about 0.37% of Amgen worth $468,384,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Baker Ellis Asset Management LLC purchased a new position in Amgen in the 3rd quarter worth approximately $108,000. Jackson Grant Investment Advisers Inc. lifted its stake in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Phocas Financial Corp. purchased a new position in Amgen in the 2nd quarter worth approximately $110,000. Omnia Family Wealth LLC lifted its stake in Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Salem Investment Counselors Inc. lifted its stake in Amgen by 4.7% in the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares in the last quarter. Institutional investors own 79.50% of the company’s stock.
A number of research analysts have weighed in on AMGN shares. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a research note on Wednesday, January 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $189.00 target price on shares of Amgen in a research note on Wednesday, January 24th. Piper Jaffray Companies reissued a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. BidaskClub lowered shares of Amgen from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Cann reissued a “buy” rating and issued a $205.00 target price on shares of Amgen in a research note on Thursday, November 30th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $191.26.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.89 EPS. equities research analysts expect that Amgen, Inc. will post 13.25 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 205.45%.
Amgen announced that its Board of Directors has initiated a share repurchase plan on Thursday, February 1st that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 4,575 shares of company stock worth $838,064. 0.19% of the stock is owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.